Annual ROE
72.50%
-67.79%-48.32%
December 31, 2023
Summary
- As of February 8, 2025, PLX annual return on equity is 72.50%, with the most recent change of -67.79% (-48.32%) on December 31, 2023.
- During the last 3 years, PLX annual ROE has risen by +48.37% (+200.46%).
- PLX annual ROE is now -86.42% below its all-time high of 533.77%, reached on December 31, 2015.
Performance
PLX ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-29.54%
+13.89%+31.98%
September 30, 2024
Summary
- As of February 8, 2025, PLX quarterly return on equity is -29.54%, with the most recent change of +13.89% (+31.98%) on September 30, 2024.
- Over the past year, PLX quarterly ROE has dropped by -124.15% (-131.22%).
- PLX quarterly ROE is now -103.05% below its all-time high of 967.94%, reached on September 30, 2021.
Performance
PLX Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
PLX ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -48.3% | -131.2% |
| 3 y3 years | +200.5% | -131.2% |
| 5 y5 years | +44.9% | -131.2% |
PLX ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -84.1% | at low | -105.3% | +98.8% |
| 5 y | 5-year | -84.1% | +200.5% | -103.0% | +98.8% |
| alltime | all time | -86.4% | +101.1% | -103.0% | +98.8% |
Protalix BioTherapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -29.54%(-32.0%) |
| Jun 2024 | - | -43.43%(-279.6%) |
| Mar 2024 | - | 24.18%(-41.1%) |
| Dec 2023 | 72.50%(-48.3%) | 41.07%(-56.6%) |
| Sep 2023 | - | 94.61%(-83.1%) |
| Jun 2023 | - | 558.69%(+174.8%) |
| Mar 2023 | - | 203.28%(+34.6%) |
| Dec 2022 | 140.29%(-69.3%) | 151.05%(-26.1%) |
| Sep 2022 | - | 204.48%(-35.8%) |
| Jun 2022 | - | 318.75%(-113.2%) |
| Mar 2022 | - | -2421.86%(+174.9%) |
| Dec 2021 | 456.96%(+1793.7%) | -881.07%(-191.0%) |
| Sep 2021 | - | 967.94%(+389.7%) |
| Jun 2021 | - | 197.64%(+191.5%) |
| Mar 2021 | - | 67.81%(+227.4%) |
| Dec 2020 | 24.13%(-7.2%) | 20.71%(+32.2%) |
| Sep 2020 | - | 15.66%(+40.8%) |
| Jun 2020 | - | 11.12%(-28.8%) |
| Mar 2020 | - | 15.61%(-42.7%) |
| Dec 2019 | 25.99%(-48.1%) | 27.23%(-28.8%) |
| Sep 2019 | - | 38.24%(-9.0%) |
| Jun 2019 | - | 42.03%(-9.8%) |
| Mar 2019 | - | 46.60%(-8.9%) |
| Dec 2018 | 50.03%(-82.3%) | 51.15%(-31.7%) |
| Sep 2018 | - | 74.85%(-33.1%) |
| Jun 2018 | - | 111.92%(+2.6%) |
| Mar 2018 | - | 109.07%(-52.7%) |
| Dec 2017 | 283.26%(-104.4%) | 230.71%(-0.8%) |
| Sep 2017 | - | 232.52%(-3.2%) |
| Jun 2017 | - | 240.33%(-23.7%) |
| Mar 2017 | - | 314.92%(-18.5%) |
| Dec 2016 | -6411.57%(-1301.2%) | 386.56%(-120.0%) |
| Sep 2016 | - | -1932.15%(+512.8%) |
| Jun 2016 | - | -315.28%(+70.9%) |
| Mar 2016 | - | -184.51%(+46.2%) |
| Dec 2015 | 533.77%(+891.2%) | -126.22%(-438.7%) |
| Sep 2015 | - | 37.27%(-22.3%) |
| Jun 2015 | - | 47.95%(-14.3%) |
| Mar 2015 | - | 55.95%(-17.5%) |
| Dec 2014 | 53.85%(-47.8%) | 67.80%(-22.5%) |
| Sep 2014 | - | 87.45%(-15.0%) |
| Jun 2014 | - | 102.87%(-25.5%) |
| Mar 2014 | - | 138.15%(-23.0%) |
| Dec 2013 | 103.13%(-70.2%) | 179.52%(-35.8%) |
| Sep 2013 | - | 279.47%(-55.6%) |
| Jun 2013 | - | 629.26%(-147.0%) |
| Mar 2013 | - | -1340.23%(-18.6%) |
| Dec 2012 | 346.08%(+147.1%) | -1647.36%(-869.2%) |
| Sep 2012 | - | 214.16%(+60.1%) |
| Jun 2012 | - | 133.73%(-47.6%) |
| Mar 2012 | - | 255.20%(-17.2%) |
| Dec 2011 | 140.08% | 308.08%(-30.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2011 | - | 442.48%(-29.8%) |
| Jun 2011 | - | 630.75%(-29.2%) |
| Mar 2011 | - | 891.15%(-147.2%) |
| Dec 2010 | -1271.84%(+1118.2%) | -1888.14%(+423.5%) |
| Sep 2010 | - | -360.70%(+62.6%) |
| Jun 2010 | - | -221.77%(+66.9%) |
| Mar 2010 | - | -132.90%(+39.4%) |
| Dec 2009 | -104.40%(+151.6%) | -95.36%(+64.8%) |
| Sep 2009 | - | -57.86%(+10.4%) |
| Jun 2009 | - | -52.42%(+17.4%) |
| Mar 2009 | - | -44.66%(+9.9%) |
| Dec 2008 | -41.50%(-43.1%) | -40.64%(-32.5%) |
| Sep 2008 | - | -60.20%(-4.5%) |
| Jun 2008 | - | -63.06%(-25.4%) |
| Mar 2008 | - | -84.53%(-14.0%) |
| Dec 2007 | -72.94%(+18.0%) | -98.32%(-5.3%) |
| Sep 2007 | - | -103.77%(-12.0%) |
| Jun 2007 | - | -117.87%(+0.2%) |
| Mar 2007 | - | -117.66%(-29.0%) |
| Dec 2006 | -61.82%(-64.6%) | -165.69%(-76.9%) |
| Sep 2006 | - | -716.40%(+18.3%) |
| Jun 2006 | - | -605.52%(+39.4%) |
| Mar 2006 | - | -434.43%(+20.8%) |
| Dec 2005 | -174.39%(-58.6%) | -359.69%(-25.9%) |
| Sep 2005 | - | -485.15%(+4.9%) |
| Jun 2005 | - | -462.65%(+4.1%) |
| Mar 2005 | - | -444.35%(+5.6%) |
| Dec 2004 | -420.89%(+2070.7%) | -420.86%(+1385.0%) |
| Sep 2004 | - | -28.34%(+13.9%) |
| Jun 2004 | - | -24.88%(+28.4%) |
| Mar 2004 | - | -19.37%(+0.5%) |
| Dec 2003 | -19.39%(+12.8%) | -19.27%(+2.7%) |
| Sep 2003 | - | -18.77%(+4.7%) |
| Jun 2003 | - | -17.93%(+2.6%) |
| Mar 2003 | - | -17.47%(+2.1%) |
| Dec 2002 | -17.19%(-40.2%) | -17.11%(+0.4%) |
| Sep 2002 | - | -17.04%(-5.3%) |
| Jun 2002 | - | -18.00%(-5.1%) |
| Mar 2002 | - | -18.96%(-36.5%) |
| Dec 2001 | -28.75%(+299.3%) | -29.85%(+7.6%) |
| Sep 2001 | - | -27.75%(+32.0%) |
| Jun 2001 | - | -21.03%(+26.0%) |
| Mar 2001 | - | -16.69%(+137.1%) |
| Dec 2000 | -7.20%(-82.2%) | -7.04%(-71.6%) |
| Sep 2000 | - | -24.76%(-26.0%) |
| Jun 2000 | - | -33.44%(+11.4%) |
| Mar 2000 | - | -30.01%(-28.1%) |
| Dec 1999 | -40.37%(-41.0%) | -41.71%(+78.8%) |
| Sep 1999 | - | -23.33%(+62.0%) |
| Jun 1999 | - | -14.40%(+17.1%) |
| Mar 1999 | - | -12.30% |
| Dec 1998 | -68.37% | - |
FAQ
- What is Protalix BioTherapeutics annual return on equity?
- What is the all time high annual ROE for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics annual ROE year-on-year change?
- What is Protalix BioTherapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics quarterly ROE year-on-year change?
What is Protalix BioTherapeutics annual return on equity?
The current annual ROE of PLX is 72.50%
What is the all time high annual ROE for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high annual return on equity is 533.77%
What is Protalix BioTherapeutics annual ROE year-on-year change?
Over the past year, PLX annual return on equity has changed by -67.79% (-48.32%)
What is Protalix BioTherapeutics quarterly return on equity?
The current quarterly ROE of PLX is -29.54%
What is the all time high quarterly ROE for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high quarterly return on equity is 967.94%
What is Protalix BioTherapeutics quarterly ROE year-on-year change?
Over the past year, PLX quarterly return on equity has changed by -124.15% (-131.22%)